Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.
Saved in:
| Title: | Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies. |
|---|---|
| Authors: | Panse J; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.; Centre for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany., Han B; Department of Hematology, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking, People's Republic of China., Cermak J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Gonzalez Fernandez FA; Hematology Service, Hospital Clínico San Carlos, Madrid, Spain., Gotoh A; Department of Hematology, Tokyo Medical University, Tokyo, Japan., Kulasekararaj AG; Department of Haematological Medicine, King's College Hospital, London, UK.; National Institute for Health Research and Wellcome King's Clinical Research Facility and King's College London, London, UK., Kyselova O; Medical Center 'Ok!Clinic+' of International Institute of Clinical Research LLC, Kyiv, Ukraine.; Institute of Hematology and Transfusiology, National Academy of Medical Science, Kyiv, Ukraine., Sahin F; Department of Hematology, Ege University, Izmir, Turkey., Scheinberg P; Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil., Schrezenmeier H; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute of Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen und University Hospital Ulm, Ulm, Germany., Straetmans N; Department of Haematology, University Hospital Saint-Luc, Brussels, Belgium., Ueda Y; Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Suita, Japan., Chang AC; Genentech, Inc., South San Francisco, CA, USA., Gentile B; Genentech, Inc., South San Francisco, CA, USA. bgentile@gmail.com., Stefani J; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Uguen M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Röth A; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. |
| Source: | Annals of hematology [Ann Hematol] 2025 Jun; Vol. 104 (6), pp. 3199-3212. Date of Electronic Publication: 2025 Jun 14. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0584 |
|---|---|
| DOI: | 10.1007/s00277-025-06449-0 |
